Hims & Hers (HIMS) Stock Surges 44% on Novo Nordisk Partnership for Weight-Loss Drugs
Hims & Hers Health (HIMS) saw its stock skyrocket over 44% in premarket trading following reports of a groundbreaking partnership with Novo Nordisk to distribute weight-loss medications. The deal, expected to be announced imminently, marks a dramatic reversal from their legal dispute earlier this year when Novo sued Hims over alleged copycat versions of its Wegovy pill.
Analysts view this as a watershed moment for HIMS. Leerink's Michael Cherny called it "both a surprise and an unabashed positive," while Morgan Stanley's Craig Hettenbach noted it could alleviate regulatory pressures on the heavily shorted stock. The news propelled HIMS from its 51% year-to-date decline into one of Monday's biggest market movers.
The collaboration represents a strategic pivot for Novo Nordisk as it seeks broader distribution channels for its blockbuster obesity treatments. For Hims, the partnership validates its telehealth platform as a legitimate conduit for pharmaceutical giants—a development that could reshape digital health economics.